Major response to imatinib mesylate in KIT-mutated melanoma

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 2046-2051

  Hodi, F Stephen ^a   Friedlander, Philip ^a   Corless, Christopher L ^b   Heinrich, Michael C ^b   Mac Rae, Suzanne ^a   Kruse, Andrea ^a   Jagannathan, Jyothi ^a   Van Den Abbeele, Annick D ^a   Velazquez, Elsa F ^c   Demetri, George D ^a   Fisher, David E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; ONCOPROTEIN; PROTEIN KIT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

AGED; ANGIONEUROTIC EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; DESQUAMATION; DRUG DOSE REDUCTION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; RECTUM RESECTION; TREATMENT RESPONSE; VAGINA BLEEDING; ANASTOMOSIS; GENETICS; IATROGENIC DISEASE; MUTATION; PATHOLOGY; RECTUM TUMOR; TUMOR RECURRENCE;

AGED; ANASTOMOSIS, SURGICAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM SEEDING; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECTAL NEOPLASMS;

EID: 42949128595     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.0707     Document Type: Article

References (20)

1. Corless CL, McGreevey L, Haley A, et al: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572, 2002
2. Patrick RJ, Fenske NA, Messina JL: Primary mucosal melanoma. J Am Acad Dermatol 56:828-834, 2007
3. Barnhill RL: Textbook of Dermatopathology (ed 2). New York, NY, McGraw-Hill Health Pub Division, 2004
4. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346, 2006
5. Antonescu CR, Busam KJ, Francone TD, et al: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257-264, 2007
6. Rubin BP, Heinrich MC, Corless CL: Gastrointestinal stromal tumour. Lancet 369:1731-1741, 2007
7. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
8. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
9. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
10. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
11. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
12. Fecher LA, Cummings SD, Keefe MJ, et al: Toward a molecular classification of melanoma. J Clin Oncol 25:1606-1620, 2007
13. Eisen T, Ahmad T, Flaherty KT, et al: Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 95:581-586, 2006
14. Wyman K, Atkins MB, Prieto V, et al: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 106:2005-2011, 2006
15. Eton O, Billings L, Kim K, et al: Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 22:717s, 2004 (suppl; abstr 7528)
16. Ugurel S, Hildenbrand R, Zimpfer A, et al: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398-1405, 2005
17. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
18. Willmore-Payne C, Holden JA, Tripp S, et al: Human malignant melanoma: Detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36:486-493, 2005
19. Willmore-Payne C, Holden JA, Hirschowitz S, et al: BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37:520-527, 2006
20. Chin L, Garraway LA, Fisher DE: Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 20:2149-2182, 2006